BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Vilanterol (removed 5/2019)

Asthma-Related Death (removed 5/2019)

  • Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol.
  • This finding with salmeterol is considered a class effect of LABA.
  • The safety and efficacy of ANORA ELLIPTA, BREO ELLIPTA, OR TRELEGY ELLIPTA in patients with asthma have not been established.¬†ANORA ELLIPTA, BREO ELLIPTA, OR TRELEGY ELLIPTA ARE not indicated for the treatment of asthma.

Patient Counseling Information

Medication Guides

Patient Medication Guide - ANORO ELLIPTA
Patient Medication Guide - BREO ELLIPTA
Patient Medication Guide - TRELEGY ELLIPTA

Package Inserts

Vilanterol

Updated November 2022